Dendritic Cell Vaccines Development for Leukemia

Alfa Cytology specialize in providing comprehensive services for the development of cell-based vaccines for leukemia. With a dedicated team of scientists and researchers, we are committed to advancing the development of effective vaccines to combat leukemia and improve patient outcomes.

Dendritic Cells-Based Therapies for Leukemia

In AML, the primary immune soldiers are precisely the cells activated by dendritic cells (DCs). Therefore, therapies based on the activation of DCs, both in vivo and in vitro, have been proposed and developed as a treatment against this leukemia. Monocytes or immature DCs are extracted, isolated, and loaded with tumor-specific antigens. The resulting monocyte-derived DCs (moDCs) are reintroduced to stimulate patient-specific T-cell responses against the tumor.

Fig. 1. DC vaccination as an immunosuppression strategy in AML. (Palomares, F. et al., 2024)

DC vaccines for leukemia hold promise as a novel therapeutic approach. However, to date, no approved DC vaccines for leukemia exist, and most research is still in the clinical stage. To provide you with cell-based vaccine development services, we utilize the most extensively studied sources of moDCs and Leukemia derived dendritic cell (DCleu) in vaccine therapy research.

Development of Ex Vivo DC-Loaded Vaccines

The key focus in developing DC vaccines lies in isolating DCs, which can be generated from autologous or allogeneic monocytes. Our development services for DC vaccines encompass the creation of autologous DC vaccines as well as allogeneic DC vaccines.

Procedures of DC Vaccine Preparation for Leukemia

In Vivo Dendritic Cell Targeting

By leveraging the mechanisms of DC surface molecules and their receptors, we offer strategies for delivering leukemia antigens into the intracellular environment of DCs. Through our services, you can achieve the desired outcomes and receive effective support for your subsequent vaccine development endeavors.

Our Service Process